Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT05224141 : A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Lung<br/>CancersCancer LocationLung
Cancers

Systemic therapy | LungSmall Cell Lung Cancer

Trial Overview Read MoreRead more

This phase III study is comparing the effectiveness of two types of immunotherapy treatments (MK-7684A and atezolizumab) when used in combination with chemotherapy (etoposide and carboplatin or cisplatin) in people with Extensive-Stage Small Cell Lung Cancer.
 

This trial is treating patients with Extensive-Stage Small Cell Lung Cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.
  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer

Commercial Sponsor

Merck

Summary

Eligible participants will be randomly allocated to either the Experimental Arm or the Active Comparator Arm. In the Experimental Arm, participants will receive 4 cycles (each cycle is 3 weeks) of a fixed-dose coformulation of 200mg pembrolizumab and 200mg vibostolimab (also known as MK7684A) every 3 weeks, in combination with 100mg/m^2 etoposide, and platinum chemotherapy (Area Under the Curve [AUC] 5 mg/mL/min carboplatin or 75mg/m^2 cisplatin)every 3 weeks for a total of approximately 12 weeks. This will then be followed by additional cycles of MK7684A every 3 weeks. In the Active Comparator Arm, participants will receive 4 cycles (each cycle is 3 weeks) of 1200mg atezolizumab every 3 weeks, in combination with 100mg/m^2 etoposide and platinum chemotherapy (AUC 5mg/mL/min carboplatin or 75mg/m^2 cisplatin) every 3 weeks for a total of approximately 12 weeks. This will then be followed by additional cycles of atezolizumab every 3 weeks.

Recruiting Hospitals Read MoreRead more

Western Health - Sunshine Hospital
St Albans
Ms Heike Raunow
CancerClinicalTrials@wh.org.au
0434 915 739

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next